Research and Markets (http://www.researchandmarkets.com/research/cpmcw2/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy-Pipeline Insights, 2016" report to their offering.

Duchenne Muscular Dystrophy-Pipeline Insights, 2016, provides in-depth insights on the pipeline drugs and their development activities around Duchenne Muscular Dystrophy. The report covers the product profiles in various stages of development, including Discovery, Pre-Clinical, IND, Phase I, Phase II, Phase III and Preregistration.

The report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Duchenne Muscular Dystrophy.

The report also assesses the Duchenne Muscular Dystrophy therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Duchenne Muscular Dystrophy
  • The report provides pipeline products under drug profile section, which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Duchenne Muscular Dystrophy and also provides company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Duchenne Muscular Dystrophy Overview
  2. Duchenne Muscular Dystrophy Pipeline Therapeutics
  3. Duchenne Muscular Dystrophy Therapeutics under Development by Companies
  4. Duchenne Muscular Dystrophy Filed and Phase III Products
  5. Comparative Analysis
  6. Duchenne Muscular Dystrophy Phase II Products
  7. Comparative Analysis
  8. Duchenne Muscular Dystrophy Phase I and IND Filed Products
  9. Comparative Analysis
  10. Duchenne Muscular Dystrophy Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Duchenne Muscular Dystrophy - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Duchenne Muscular Dystrophy - Discontinued Products
  19. Duchenne Muscular Dystrophy - Dormant Products
  20. Companies Involved in Therapeutics Development for Duchenne Muscular Dystrophy

For more information visit http://www.researchandmarkets.com/research/cpmcw2/duchenne_muscular.